DR2313

DR2313 is a potent, selective, competitive and brain-penetrant inhibitor of poly (ADP-ribose) polymerase (PARP), with IC50s of 0.20 μM and 0.24 μM for PARP-1 and PARP-2, respectively. DR2313 exhibits neuroprotective effects on ischemic injuries in vitro and in vivo[1][2].

Product Specifications

CAS Number

[284028-90-6]

UNSPSC

12352005

Hazard Statement

H302-H315-H319-H335

Target

PARP

Type

Reference compound

Related Pathways

Cell Cycle/DNA Damage; Epigenetics

Applications

Neuroscience-Neuromodulation

Field of Research

Neurological Disease

Assay Protocol

https://www.medchemexpress.com/dr2313.html

Purity

99.66

Solubility

DMSO : 12.5 mg/mL (ultrasonic) |H2O : ≥ 100 mg/mL

Smiles

O=C1C(CSCC2)=C2NC(C)=N1

Molecular Formula

C8H10N2OS

Molecular Weight

182.25

Precautions

P261-P264-P270-P271-P280-P302+P352-P304+P340-P305+P351+P338-P330-P362+P364-P403+P233-P405-P501

References & Citations

[1]Nakajima H, et, al. A newly synthesized poly (ADP-ribose) polymerase inhibitor, DR2313 [2-methyl-3,5,7,8-tetrahydrothiopyrano[4,3-d]-pyrimidine-4-one]: pharmacological profiles, neuroprotective effects, and therapeutic time window in cerebral ischemia in rats. J Pharmacol Exp Ther. 2005 Feb;312 (2) :472-81.|[2]Xu Z, et, al. Endonuclease G does not play an obligatory role in poly (ADP-ribose) polymerase-dependent cell death after transient focal cerebral ischemia. Am J Physiol Regul Integr Comp Physiol. 2010 Jul;299 (1) :R215-21.